vs
Side-by-side financial comparison of ARROWHEAD PHARMACEUTICALS, INC. (ARWR) and PicoCELA Inc. (PCLA). Click either name above to swap in a different company.
ARROWHEAD PHARMACEUTICALS, INC. is the larger business by last-quarter revenue ($264.0M vs $252.6M, roughly 1.0× PicoCELA Inc.). ARROWHEAD PHARMACEUTICALS, INC. runs the higher net margin — 11.7% vs -125.2%, a 136.9% gap on every dollar of revenue. ARROWHEAD PHARMACEUTICALS, INC. produced more free cash flow last quarter ($11.3M vs $-256.6M).
Arrowhead Pharmaceuticals, Inc. is a publicly traded biopharmaceutical company based in Pasadena, California. Arrowhead's products in development act through RNA interference (RNAi) mechanisms of action. The company focuses on treatments for hepatitis B, liver disease associated with alpha 1-antitrypsin deficiency and cardiovascular disease.
PicoCELA Inc. is a global technology company specializing in low-power, high-reliability wireless connectivity solutions, including Wi-Fi HaLow modules and edge network infrastructure. It caters to industrial IoT, smart city, retail, and smart home segments, with a primary operational footprint across Asia, North America, and European markets.
ARWR vs PCLA — Head-to-Head
Income Statement — Q1 FY2026 vs Q2 FY2025
| Metric | | |
|---|---|---|
| Revenue | $264.0M | $252.6M |
| Net Profit | $30.8M | $-316.2M |
| Gross Margin | — | — |
| Operating Margin | 15.5% | -114.8% |
| Net Margin | 11.7% | -125.2% |
| Revenue YoY | 10461.3% | — |
| Net Profit YoY | 117.8% | — |
| EPS (diluted) | $0.22 | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $715.0M | $456.8M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $568.4M | $354.8M |
| Total Assets | $1.6B | $1.2B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $715.0M | — | ||
| Q1 25 | — | $456.8M |
| Q4 25 | $568.4M | — | ||
| Q1 25 | — | $354.8M |
| Q4 25 | $1.6B | — | ||
| Q1 25 | — | $1.2B |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $13.5M | $-245.6M |
| Free Cash FlowOCF − Capex | $11.3M | $-256.6M |
| FCF MarginFCF / Revenue | 4.3% | -101.6% |
| Capex IntensityCapex / Revenue | 0.8% | 4.3% |
| Cash ConversionOCF / Net Profit | 0.44× | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $13.5M | — | ||
| Q1 25 | — | $-245.6M |
| Q4 25 | $11.3M | — | ||
| Q1 25 | — | $-256.6M |
| Q4 25 | 4.3% | — | ||
| Q1 25 | — | -101.6% |
| Q4 25 | 0.8% | — | ||
| Q1 25 | — | 4.3% |
| Q4 25 | 0.44× | — | ||
| Q1 25 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ARWR
Segment breakdown not available.
PCLA
| Revenue from product | $179.1M | 71% |
| Revenue from SaaS, Maintenance and others | $42.4M | 17% |
| Revenue from product – related party | $31.0M | 12% |
